Target
Dexamethasone
26 abstracts
Abstract
DREAMM-7 update: Subgroup analyses from a phase 3 trial of belantamab mafodotin (belamaf) + bortezomib and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM).Org: Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Centro de Investigación del Cáncer (IBMCC-USAL, CSIC), Medical University of Lodz, Samodzielny Publiczny Szpital Kliniczny,
Abstract
DIET2TREAT: A randomized, multi-center, phase 2 trial of a ketogenic diet vs standard dietary guidance in combination with standard-of-care treatment for patients with newly diagnosed glioblastoma.Org: Providence Saint John’s Health Center, Santa Monica, CA, Milwaukee, WI, Cedars-Sinai Cancer,
Abstract
Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM).Org: Princess Margaret Cancer Centre, Ankara University, University Hospital Brno, General Hospital Evangelismos, Athens, Greece, St. Vincent's Hospital Melbourne,
Abstract
Tolerability and efficacy of BrECADD versus BEACOPP in advanced stage classical Hodgkin lymphoma: GHSG HD21, a randomized study.Org: University Hospital of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), German Hodgkin Study Group (GHSG), Swiss Group for Clinical Cancer Research (SAKK), Department of Internal Medicine III with Hematology,
Abstract
Safety results from the phase 3 MajesTEC-7 study in patients (pts) with transplant ineligible/not intended newly diagnosed multiple myeloma (NDMM).Org: Centre Hospitalier Universitaire de Nantes, Ankara University, University of Athens, School of Medicine, Showa University, Memorial Sloan Kettering Cancer Center,
Abstract
Ambulatory teclistamab administration in patients with relapsed/refractory multiple myeloma.Org: Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University,
Abstract
Evaluation of elranatamab vs EPd, PVd, or Kd in patients with relapsed or refractory multiple myeloma and prior anti-CD38–directed therapy: MagnetisMM-32.Org: UCHealth Cancer Care and Hematology, Department of Hematology, Yamagata University Hospital,
Abstract
Impact of renal impairment (RI) on pharmacokinetics (PK) and clinical outcomes with mezigdomide plus dexamethasone (DEX) in relapsed/refractory multiple myeloma (RRMM).Org: NIHR UCLH Clinical Research Facility, Department of Clinical Haematology,
Abstract
Frontline treatment with zanubrutinib plus rituximab (ZR) followed by short course R-DHAOx in patients with mantle cell lymphoma (MCL): Results of the phase II CHESS clinical trial.Org: Department of Hematology, Huizhou Municipal Central Hospital, Department of Medical Oncology, The Second Hospital of Dalian Medical University, Department of Hematology, The First Affiliated Hospital of Guangdong Pharmaceutical University,
Abstract
Physical activity and dexamethasone for cancer related fatigue: A preliminary placebo controlled randomized control trial.Org: The University of Texas MD Anderson Cancer Center, Houston, TX, USA,
Abstract
First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma.Org: University College London Cancer Institute, University Hospital of Salamanca/IBSAL/CIC/CIBERONC, Medical College of Wisconsin, Peter MacCallum Cancer Centre, Melbourne, Australia, Hematology Clinic,
Abstract
Safety and clinical activity of belantamab mafodotin plus lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma: The phase 1/2, prospective, open-label, BelaRd study.Org: Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Attica, Greece, Health Data Specialists, Dublin, Ireland, Dublin, Ireland, Alexandra Hospital, Athens, Greece,
Abstract
Physical and emotional quality of life in children with B-acute lymphoblastic leukemia randomized to every 4- vs. 12-week vincristine/dexamethasone during maintenance: Children’s Oncology Group AALL0932.Org: Children's Oncology Group Data Center, Yale University Hematology/Oncology, St. Jude Children's Research Hospital, Children's National Medical Center, Washington, DC, University of Texas Southwestern Medical Center,
Abstract
Safety and preliminary efficacy of intrathecal (IT) and intravenous (IV) nivolumab (N) for patients (pts) with leptomeningeal disease (LMD).Org: MD Anderson Cancer Center, University of Texas MD Anderson Cancer Center, U T MD Anderson Cancer Center, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Treatments and outcomes of patients with localized extranodal NK/T-cell lymphoma (ENKL) diagnosed between 2014 and 2021: A cooperative study in Japan.Org: Mie University Graduate School of Medicine, Tsu, Japan, Shimane University Hospital, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Nagano Prefectural Shinshu Medical Center, National Cancer Center Hospital East, Kashiwa, Japan,
Abstract
A phase I/II study of carfilzomib, iberdomide (CC-220), and dexamethasone (KID) in patients with newly diagnosed transplant-eligible multiple myeloma.Org: John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ, Hackensack University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, Center for Discovery and Innovation, Hackensack Meridian Health, Hackensack Meridian Health,
Abstract
A phase III, double-blind, non-inferiority, randomized controlled trial of antiemetic prophylaxis for highly emetogenic chemotherapy without dexamethasone: CINV POD study.Org: Cancer Institute of Jiangsu Province,
Abstract
Dexamethasone and exercise for cancer-related fatigue: A phase III randomized controlled trial.Org: Tata Memorial Centre, Tata Memorial Hospital (HBNI), Tata Memorial Centre (HBNI),
Abstract
Comparing the time toxicity of cancer treatments in the CCTG LY.12 trial.Org: University of Minnesota Masonic Cancer Center, Minneapolis, MN, Queen's University, Belfast, Princess Margaret - University Health Network, Canadian Cancer Trials Group, NCIC Clinical Trials Group,
Abstract
A phase IIb study of selinexor in combination with carfilzomib, daratumumab, or pomalidomide in patients with multiple myeloma relapsing on current therapy.Org: John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ, Hackensack University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, Center for Discovery and Innovation, Hackensack Meridian Health, Hackensack Meridian Health,
Abstract
ACCLAIM-1 dose escalation: Determination of quaratusugene ozeplasmid and osimertinib recommended phase 2 dose (RP2D).Org: Valkyrie Clinical Trials, Inc, Rocky Mountain Cancer Centers, Millennium Oncology, Virginia Cancer Specialists, Genprex,
Abstract
A novel risk assessment metric for antimyeloma therapies and drug interactions.Org: Kansas State University–Olathe, DATA Consortium, Computational Comparative Medicine, Department of Mathematics, Università degli Studi di Genova, San Martino, Italy, Myeloma Program,
Abstract
Real-world treatment patterns of triple-class refractory (TCR) multiple myeloma (MM) across the United States (US), Canada, and western Europe: A retrospective chart study.Org: Cerner Enviza, Pfizer Inc., London, United Kingdom,
Abstract
Association of venetoclax-based therapy with increased survival in multiple myeloma (MM) harboring t(11;14): A single-center experience.Org: H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morsani College of Medicine,
Abstract
Ocular adverse events in transplant ineligible patients with newly diagnosed multiple myeloma treated with belantamab mafodotin plus lenalidomide/dexamethasone from the phase 1/2 BelaRd study.Org: Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Attica, Greece, Health Data Specialists, Dublin, Ireland, Dublin, Ireland, Alexandra Hospital, Athens, Greece, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Attica, Greece, Health Data Specialists, Dublin, Ireland, Alexandra Hospital, Athens, Greece,
Abstract
Incidence of second primary malignancies (SPMs) in patients with multiple myeloma (MM) receiving anti-CD38 monoclonal antibodies (mAbs): A systematic review and meta-analysis.Org: Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ, Massachusetts General Hospital, Boston, MA, USA, The University of Arizona, Tucson, AZ, Faculty of Health Sciences, Hamilton, ON, Canada,